Bafna Pharmaceuticals is a Chennai-based maker of generic tablets and capsules that rebuilt itself from the ground up - it went through a court-supervised insolvency process in 2019, wiped its debts clean, and emerged under new ownership with a simple philosophy: chase profits, not just revenue. The company operates a single, internationally accredited factory where it manufactures medicines both for its own export labels and on contract for large global pharma companies, treating R&D as the engine that feeds both sides of the business.
Business segments
A single manufacturing engine powers two intertwined revenue streams - making medicines under its own labels for export markets, and making them on contract for other pharma companies - both fed by the same R&D and regulatory backbone.
1. Contract manufacturing: the factory that works for other pharma companies
Bafna earns a fee for every batch of tablets and capsules it makes on behalf of global pharma companies, using their formulas and its own accredited factory.
- Paid per batch dispatched - the company manufactures products under fixed-period, annually renewable contracts, and recognises revenue only when each finished batch leaves the factory and is invoiced to the customer.
- One factory, many masters - all contract manufacturing runs through a single facility at Red Hills, Chennai, which holds UK-MHRA, EU-GMP, TGA-Australia and WHO-GMP certifications - the regulatory stamps that make it acceptable to pharma companies in regulated markets.
- Small batches to large ones - the plant can handle everything from small development runs to full-scale commercial production, with an installed capacity of roughly 1,000 million tablet units a year and utilisation running at about 90%.
- Customers are the creditworthy kind - the company works with entities of repute that carry good credit reports, and sometimes receives advances from them before manufacturing begins.
- More than just pressing pills - the service extends into contract research and manufacturing (CRAMS), technology transfers, and formulation and analytical development, making it a one-stop shop for a pharma partner that wants to outsource everything from lab to finished product.
2. Own-label generics: medicines sold under the Bafna name abroad
The company registers its own generic products in over 20 countries and sells them through local distributors - a portfolio built on complex, hard-to-copy formulations.
- Exports are the main event - more than 70% of total revenue comes from selling Bafna's own generic products into markets across Asia, Africa, the UK, Europe and Australia.
- Registrations are the entry ticket - the company holds active product registrations in more than 20 countries, with over 200 products still pending approval across Africa, Asia and the rest of the world, so the revenue pipeline is essentially a queue of regulatory filings.
- Local distributors, multiple products - in major geographies like Nigeria, the Philippines, Sri Lanka, Tanzania and Nepal, Bafna operates through multiple registered product lines, each tied to a dedicated local distributor with established networks in wholesale and government tenders.
- First to market with a coated generic - the company was the first to launch Generic Prednisolone Eccentric Coated (a steroid used for swelling and allergic reactions) in the UK and other markets, signalling its ability to tackle niche, technically demanding products.
- Therapeutic spread reduces reliance on any one drug - the portfolio spans cardiology (beta blockers, ACE inhibitors, statins), lifestyle and potent drugs (oncology, women's health, diabetes), and pain management (neuropathic, joint and opioid pain), so demand is not tied to a single disease category.
R&D and regulatory engine
The same R&D lab and regulatory team feeds both the contract business and the own-label export business - developing formulations, proving they work, and getting them approved in multiple countries.
- DSIR-recognised lab - the R&D facility is recognised by India's Department of Scientific and Industrial Research, and it develops everything from delayed-release and sustained-release tablets to chewable, orally disintegrating and liquid dosage forms.
- Taste-masking and coating know-how - the lab uses ion-exchange resins to mask bitter drugs and multi-layer coating technology for pH-sensitive products that need intestinal release and gastric resistance, which is how the company tackles complex generics that are harder for competitors to replicate.
- Regulatory cell tracks every dossier - a dedicated Regulatory Affairs team handles real-time dossier submissions and tracks approvals across all target markets, while an in-house quality control lab equipped with high-pressure liquid chromatography, gas chromatography and atomic absorption spectrometers ensures every batch meets the standards of the relevant regulator.
- Over 200 products in the approval queue - as of FY23, the company had 186 registered products and 232 applications pending globally, with the largest clusters in Nigeria, the Philippines, Nepal, Sri Lanka and Ethiopia - so the commercial pipeline is visible and countable in regulatory filings.
Group structure and partners
Bafna Pharmaceuticals is a standalone company with no subsidiaries, controlled by a single majority shareholder that rescued it through a court-approved turnaround.
- Controlled by SRJR Lifesciences LLP - the holding company acquired an 88.30% stake through a preferential allotment of shares at Rs. 26 apiece, as part of an NCLT-approved resolution plan under the Insolvency and Bankruptcy Code that extinguished all outstanding liabilities and left the company debt-free.
- The old subsidiary is gone - a previous subsidiary, Bafna Life Styles Remedies Limited, had no operations since September 2016 after its facility was disqualified by a customer, and its name was struck off during FY21.
- No foreign debt or investment - the company has no Foreign Direct Investment, no Overseas Direct Investment and no External Commercial Borrowing, keeping its capital structure simple and domestic.